Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone and ECT for Treatment Resistant Depression
NCT00203723Phase 4Terminated
- Sponsor
- University of California, Los Angeles
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in treatment-resistant depression (TRD) (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Hamilton Rating Scale for Depression and Montgomery-Asberg Depression Rating Scale. Started Mar 2005; status: terminated.
02
Drugs
risperidone
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT00203723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203723.